Biodistribution of liposomal 131I-VIP in rat using gamma camera

Nuclear Medicine and Biology

Volumn 26, Issue 8, 1999, Pages 931-936

  Refai, Essam ^a   Jonsson, Cathrine ^b   Andersson, Mats ^a   Jacobsson, Hans ^b   Larsson, Stig ^b   Kogner, Per ^b   Hassan, Moustapha ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Distribution; Gamma camera; Liposomal VIP; Pharmacokinetics; VIP

Indexed keywords

IODINE 131; LIPOSOME; VASOACTIVE INTESTINAL POLYPEPTIDE; DIAGNOSTIC AGENT; DRUG CARRIER; IODINATED VASOACTIVE INTESTINAL PEPTIDE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG UPTAKE; LUNG; MALE; NONHUMAN; RADIOACTIVITY; RAT; SCINTILLATION CAMERA; ANIMAL; HALF LIFE TIME; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; AREA UNDER CURVE; DRUG CARRIERS; GAMMA CAMERAS; HALF-LIFE; IODINE RADIOISOTOPES; LIPOSOMES; MALE; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0033233299     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(99)00062-1     Document Type: Article

References (26)

1. Barnes P.J., Dixon C.M.S. The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am. Rev. Resp. Dis. 130:1984;162-166.
2. Barrowcliffe M.P., Morice A., Jones J.G., Sever P.S. Pulmonary clearance of vasoactive intestinal peptide. Thorax. 41:1986;88-93.
3. Bolin D. R., Cottrell J., Michalewsky J., Garippa R., O'Neil N., Simko B. and O'Donnell M. (1992) Degradation of vasactive intestinal peptide in bronchial alveolar lavage fluid. In: Vasoactive Intestinal Peptide and Related Peptides (Edited by Yanaihara N.), pp. 25-30, Kande Chiyodaku, Tokyo. 13.
4. Bolin D.R., Michalewsky J., Wasserman M.A., O'Donnell M. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers. 37:(2):1995;57-66.
5. Borgström P., Hassan M., Wassbery E., Refai E., Jonsson C., Larsson S., Jacobsson H., Kogner P. The somatostatin analouge octreotide inhibits neuroblastoma growth in vivo. Pediat. Res. 46:1999;328-332.
6. Coles S.T., Said S.I., Reid L.M. Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro. Am. Rev. Resp. Dis. 124:1981;531-536.
7. Gao X.P., Noda Y., Rubinstein I., Paul S. Vasoactive intestinal peptide encapsulation in liposomes Effects on systemic arterial blood pressure . Life Sci. 54:1994;247-252.
8. Gololobov G., Noda Y., Sherman S., Rubinstein I., Baranowska-Kortylewicz J., Paul S. Stabilization of vasoactive intestinal peptide by lipids. J. Pharmacol. Exp. Ther. 285:1998;753-758.
9. 131I-VIP in the rat studied by gamma-camera. Nucl. Med. Biol. 21:1994;865-872.
10. Kogner P., Borgström P., Bjelleru P., Schilling F.H., Dominici C., Bihl H., Jacobsson H., Theodorsson E., Wassbery E., Refai E., Hassan M. Somatostin in neuroblastoma and ganglioneuroma. Eur. J. Cancer. 33:1997;2084-2089.
11. Marie J.C., Boissard C., Rosselin G. Purificaton of monoiodinated vasointestinal peptide (M 125I-VIP) by high pressure liquid chromatography (HPLC). Peptides. 5:1984;179-182.
12. Mojarad M., Grode T. L., Cox C., Kimmel G. and Said S. I. (1985) Differential responses of human asthmatics to inhaled vasoactive intestinal peptide (VIP). Am. Rev. Resp. Dis. 131, Supp A281.
13. Mutt V., Söderberg U. On the assay of secretin. Arkiv för kemi. 15:1959;63-68.
14. Ollerenshaw S., Jarvis D., Woolcock A., Sullivan C., Schieber T. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N. Engl. J. Med. 320:1989;1244-1248.
15. Ostro J.M. Liposomes from Biophysics to Therapeutics. 1987;Marcel Dekker, New York.
16. Paul S., Volle D.J., Beach C.M., Johnson D.R., Powell M.J., Massey R.J. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 244:1989;1158-1162.
17. Said S. I. (Ed.) (1982) Vasoactive Intestinal Peptide. Advances in Peptide Hormone Research Series. Raven Press, New York.
18. Said S.I. Vasoactive intestinal peptide. Biological role in health and disease. Trends Endocrinol. Metab. 2:1991;107-112.
19. Said S.I. VIP in asthma. Ann. NY Acad. Sci. 629:1991;305-318.
20. Said S.I. Vasoactive intestinal peptide (VIP) and related peptides as anti-asthma and anti-inflamatory agents. Biomed. Res. 13:(suppl. 2):1992;257-262.
21. Said S.I., Mutt V. Polypeptide with broad biological activity. Isolation from small intestine. Science. 169:1970;1217-1218.
22. Said S.I., Mutt V. Isolation from procine-intestinal wall a vasoactive octacosapeptide related to secretin and glucagon. Eur. J. Biochem. 28:1972;199-204.
23. Sejourne F., Suzuki H., Alkan-Onyukesl H. Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo. Am. J. Physiol. 271:1997;282-287.
24. Suzuki H., Noda Y., Gao X.P., Alkan-Onyukesl H., Paul S., Rubinstein I. Encapsulation of VIP into liposomes restore vasorelation in hypertension. Am. J. Physiol. 271:1996;282-292.
25. Suzuki H., Noda Y., Paul S., Gao X.P., Rubinstein I. Encapsulation of vasoactive intestinal peptide into liposomes Effects on vasodilation in vivo . Life Sci. 57:1995;1451-1457.
26. Virgolini I., Raderer M., Kurtaran A., Angelberger P., Banyai S., Wang Q., Shuren L., Banyai M., Pidlich J., Niederle B., Scheithauer W., Valent P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinmoas and endocrine tumors. N. Engl. J. Med. 331:1994;1116-1121.